Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-1305是一种新型抗心律失常化合物,主要阻断哺乳动物细胞和心室心肌细胞中 IKr 的快速组分、l 型钙电流和病房内钠电流,可用于研究逆转心律失常。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,480 | 现货 | ||
5 mg | ¥ 3,720 | 现货 | ||
10 mg | ¥ 5,350 | 现货 | ||
25 mg | ¥ 8,290 | 现货 | ||
50 mg | ¥ 10,900 | 现货 | ||
100 mg | ¥ 14,800 | 现货 | ||
500 mg | ¥ 29,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,110 | 现货 |
产品描述 | AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias. |
靶点活性 | Inalate:4.3 microM, Inapeak:66 microM |
体外活性 | AZD1305 (0.1–30 µM, n = 6, each concentration applied for 3 min ; dog cardiomyocytes) concentration-dependently blocked INalate (IC50=4.3 microM) and INapeak (IC50=66 microM). In PFs, E-4031, but not AZD1305, markedly prolonged APD90 (from 380+/-15 to 597+/-86 ms, P<0.05) after the long CL and augmented APD90 instability (2+/-0.4 to 24+/-6.1 ms, P<0.05), increases significantly attenuated by AZD1305 and lidocaine.[3] |
体内活性 | AZD1305 ((36g/kg/min intravenously for 30 minutes ; anesthetized mongrel dogs) respectively increased QT and RR intervals from 290±7 to 397±15 ms (+37%, P<0.0001) and from 603±22 to 778±32 ms (+29%, P=0.002) at normal sinus rhythm. AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P<0.0001). AZD1305 slightly slowed the idioventricular rhythm.[2] |
别名 | UNII-CZO834LXQM, AZD 1305 |
分子量 | 434.5 |
分子式 | C22H31FN4O4 |
CAS No. | 872045-91-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (57.54 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3015 mL | 11.5075 mL | 23.015 mL | 57.5374 mL |
5 mM | 0.4603 mL | 2.3015 mL | 4.603 mL | 11.5075 mL | |
10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL | 5.7537 mL | |
20 mM | 0.1151 mL | 0.5754 mL | 1.1507 mL | 2.8769 mL | |
50 mM | 0.046 mL | 0.2301 mL | 0.4603 mL | 1.1507 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD-1305 872045-91-5 Others AZD1305 UNII-CZO834LXQM AZD 1305 Inhibitor inhibitor inhibit